Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The study duration is one year; post treatment safety follow up visit will be conducted 4 weeks after the patient takes the last dose of teriflunomide
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age of patients ≥ 18 years
Patients with relapsing form of multiple sclerosis at time of screening visit.
Signed written informed consent.
You may not be if
Patients with hypersensitivity to teriflunomide, leflunomide, or to any excipients in the tablets.
Liver function impairment or persisting elevations of serum glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), greater than two times the upper limit of normal (ULN) during screening visit.
Known history of pre-existing acute or chronic liver disease.
Patients with significantly (as per Investigator's discretion) impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia.
Known history of severe immunodeficiency, acute or severe active infections.
Female patients with a positive pregnancy test at screening or women of child-bearing potential who do not agree to use effective methods of contraception throughout the course of the study.
Male patients unwilling to use reliable contraception during the course of the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis
